APLS vs. MXL
APLS (Apellis Pharmaceuticals, Inc.) and MXL (MaxLinear, Inc.) are both stocks. APLS operates in Biotechnology (Healthcare), while MXL operates in Semiconductors (Technology). Over the past 5 years, APLS returned -1.50%/yr vs 19.10%/yr for MXL. At a 0.23 correlation, their price movements are largely independent.
Performance
APLS vs. MXL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, APLS achieves a 63.34% return, which is significantly lower than MXL's 424.33% return.
APLS
- 1D
- 0.00%
- 1M
- 0.15%
- YTD
- 63.34%
- 6M
- 93.08%
- 1Y
- 118.01%
- 3Y*
- -22.49%
- 5Y*
- -1.50%
- 10Y*
- —
MXL
- 1D
- 2.96%
- 1M
- 16.99%
- YTD
- 424.33%
- 6M
- 409.70%
- 1Y
- 658.42%
- 3Y*
- 46.90%
- 5Y*
- 19.10%
- 10Y*
- 16.09%
APLS vs. MXL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
APLS Apellis Pharmaceuticals, Inc. | 63.34% | -21.28% | -46.69% | 15.76% | 9.37% | -17.34% | 86.81% | 132.15% | -39.22% | 54.67% |
MXL MaxLinear, Inc. | 424.33% | -11.88% | -16.79% | -29.99% | -54.97% | 97.41% | 79.97% | 20.57% | -33.38% | 1.46% |
Correlation
The correlation between APLS and MXL is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Nov 10, 2017 | 0.23 |
Fundamentals
APLS:
$1.41
MXL:
-$1.52
APLS:
3.77
MXL:
15.65
APLS:
$1.03B
MXL:
$508.90M
APLS:
$920.13M
MXL:
$289.93M
APLS:
$176.85M
MXL:
-$70.54M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
APLS vs. MXL — Risk / Return Rank
APLS
MXL
APLS vs. MXL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and MaxLinear, Inc. (MXL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| APLS | MXL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -5.27 | ||
| Sortino ratioReturn per unit of downside risk | -2.31 | ||
| Omega ratioGain probability vs. loss probability | 1.58 | 1.78 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | 3.37 | 24.79 | -21.42 |
| Martin ratioReturn relative to average drawdown | 7.45 | 67.14 | -59.69 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| APLS | MXL | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.99 | 6.26 | -5.27 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.02 | 0.25 | -0.27 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.25 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.16 | 0.17 | -0.01 |
Drawdowns
APLS vs. MXL - Drawdown Comparison
The maximum APLS drawdown since its inception was -82.47%, smaller than the maximum MXL drawdown of -88.13%. Use the drawdown chart below to compare losses from any high point for APLS and MXL.
Loading charts...
Drawdown Indicators
| APLS | MXL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -82.47% | -88.13% | +5.66% |
Max Drawdown (1Y)Largest decline over 1 year | -43.53% | -26.81% | -16.72% |
Max Drawdown (3Y)Largest decline over 3 years | -82.47% | -73.61% | -8.86% |
Max Drawdown (5Y)Largest decline over 5 years | -82.47% | -88.13% | +5.66% |
Max Drawdown (10Y)Largest decline over 10 years | — | -88.13% | — |
Current DrawdownCurrent decline from peak | -56.03% | -10.64% | -45.39% |
Average DrawdownAverage peak-to-trough decline | -37.13% | -45.07% | +7.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.63% | 9.88% | +9.75% |
Volatility
APLS vs. MXL - Volatility Comparison
The current volatility for Apellis Pharmaceuticals, Inc. (APLS) is 0.54%, while MaxLinear, Inc. (MXL) has a volatility of 28.83%. This indicates that APLS experiences smaller price fluctuations and is considered to be less risky than MXL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| APLS | MXL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 0.54% | 28.83% | -28.29% |
Volatility (6M)Calculated over the trailing 6-month period | 91.44% | 80.78% | +10.66% |
Volatility (1Y)Calculated over the trailing 1-year period | 147.98% | 106.15% | +41.83% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.01% | 76.53% | +14.48% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.60% | 65.50% | +18.10% |
Dividends
APLS vs. MXL - Dividend Comparison
Neither APLS nor MXL has paid dividends to shareholders.
Financials
APLS vs. MXL - Financials Comparison
This section allows you to compare key financial metrics between Apellis Pharmaceuticals, Inc. and MaxLinear, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
APLS vs. MXL - Profitability Comparison
APLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported a gross profit of 151.46M and revenue of 192.01M. Therefore, the gross margin over that period was 78.9%.
MXL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, MaxLinear, Inc. reported a gross profit of 78.88M and revenue of 137.19M. Therefore, the gross margin over that period was 57.5%.
APLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported an operating income of 26.47M and revenue of 192.01M, resulting in an operating margin of 13.8%.
MXL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, MaxLinear, Inc. reported an operating income of -17.21M and revenue of 137.19M, resulting in an operating margin of -12.5%.
APLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported a net income of 18.66M and revenue of 192.01M, resulting in a net margin of 9.7%.
MXL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, MaxLinear, Inc. reported a net income of -45.14M and revenue of 137.19M, resulting in a net margin of -32.9%.
Frequently Asked Questions
APLS and MXL have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MXL has higher volatility (28.83%) compared to APLS (0.54%). In terms of maximum drawdown, APLS dropped -82.47% vs MXL's -88.13%.
MXL currently has the higher Sharpe Ratio (6.26 vs 0.99), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for APLS and MXL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer